Developmental and epileptic encephalopathy, 13
MONDO:0013801Any early infantile epileptic encephalopathy in which the cause of the disease is a mutation in the SCN8A gene.
Also known as: DEE13, EIEE13, SCN8A early infantile epileptic encephalopathy, developmental and epileptic encephalopathy 13, early infantile epileptic encephalopathy caused by mutation in SCN8A, early infantile epileptic encephalopathy-13, epileptic encephalopathy, early infantile, 13, epileptic encephalopathy, early infantile, type 13
20 clinical trials for this condition and its sub-types, 3 tagged with Developmental and epileptic encephalopathy, 13 itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New hope for Hard-to-Treat seizures: phase 3 trial launches
Disease control OngoingThis study tests an experimental drug called LP352 to see if it can safely reduce seizures in children and adults with developmental and epileptic encephalopathies (DEE), a group of severe epilepsy syndromes. About 320 participants will receive either LP352 or a placebo, and rese…
Phase 3 • Sponsor: Longboard Pharmaceuticals • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New drug LP352 aims to control seizures in severe epilepsy over the long term
Disease control By invitation onlyThis phase 3 study is testing the long-term safety and effectiveness of LP352 (Bexicaserin) in 324 children and adults with developmental and epileptic encephalopathy (DEE), including Dravet and Lennox-Gastaut syndromes. Participants who completed earlier studies will receive LP3…
Phase 3 • Sponsor: Longboard Pharmaceuticals • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New hope for kids with rare epilepsy: drug trial targets seizure control
Disease control OngoingThis study tests an investigational drug called relutrigine in 160 children with a severe form of epilepsy called developmental and epileptic encephalopathy (DEE). The goal is to see if the drug can safely reduce monthly seizure frequency compared to a placebo. After the initial …
Phase 3 • Sponsor: Praxis Precision Medicines • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Real-World study tracks Epidyolex's Long-Term impact on seizures
Disease control OngoingThis study follows 158 people in France who are prescribed Epidyolex (a cannabidiol-based medicine) for seizures as part of their normal care. Researchers will track how long people stay on the treatment, side effects, seizure frequency, and changes in daily functioning and quali…
Sponsor: Jazz Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for kids with hard-to-treat genetic seizures
Disease control OngoingThis study tests a new medicine called PRAX-562 in 77 children with rare genetic epilepsies (SCN2A or SCN8A). The goal is to see if it safely reduces motor seizures. The trial has two parts: a double-blind phase where some children get the drug and some get a placebo, followed by…
Phase 2/3 • Sponsor: Praxis Precision Medicines • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Could a urea cycle drug help kids with rare epilepsy?
Disease control OngoingThis early-phase trial is testing whether glycerol phenylbutyrate (Ravicti), a drug already approved for a different condition, is safe and tolerable for children with genetic disorders like STXBP1 and SLC6A1 that cause seizures and developmental delays. The study will enroll 50 …
Early phase 1 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New inhaler aims to stop prolonged seizures fast and safely
Symptom relief By invitation onlyThis study tests the long-term safety of an inhaled medication called Staccato alprazolam for people aged 12 and older who have prolonged seizures. About 300 participants will use the inhaler when a seizure starts to see if it stops the seizure quickly and without serious side ef…
Phase 3 • Sponsor: UCB Biopharma SRL • Aim: Symptom relief
Last updated Aug 16, 2026 00:00 UTC